US 12,472,227 B2
Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
Jya-Wei Cheng, Tainan (TW); Hsi-Tsung Cheng, Tainan (TW); Hui-Yuan Yu, Tainan (TW); Su-Ya Hsu, Tainan (TW); and Wei-Chen Lee, Tainan (TW)
Assigned to RISE BIOPHARMACEUTICALS INC., Beijing (CN)
Filed by Rise Biopharmaceuticals Inc., Beijing (CN)
Filed on Jan. 8, 2021, as Appl. No. 17/144,823.
Application 17/144,823 is a continuation in part of application No. 17/006,512, filed on Aug. 28, 2020.
Application 17/006,512 is a continuation in part of application No. 15/569,033, abandoned, previously published as PCT/CN2015/008725, filed on Jun. 3, 2015.
Claims priority of provisional application 62/959,553, filed on Jan. 10, 2020.
Prior Publication US 2021/0128683 A1, May 6, 2021
Int. Cl. A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/1709 (2013.01) [A61P 35/00 (2018.01); A61K 45/06 (2013.01)] 3 Claims
 
1. A method of treating a gemcitabine-resistant pancreatic cancer, comprising:
administering a chemokine receptor antagonistic modified peptide combined with gemcitabine in a therapeutically effective amount to the gemcitabine-resistant pancreatic cancer subject in need thereof,
wherein the chemokine receptor antagonistic modified peptide is ONCO P-8 set forth in SEQ ID NO: 1.